Angel Biotech has seen a continuation of the 'very difficult' market conditions since mid-September, with funding constraints of clients forcing delays and changed priorities with a number of potential customers. However, the group is currently seeing an upturn in the volume of enquiries and bids, especially in areas opened up by the group's wider commercial offering in biomedical collagen. "Success in the completion of the tasks and delivery of earnings is fundamental and the board and the group's management are clear on what is expected of them," the firm said.
Alliance Pharma, a speciality pharmaceutical company, has said its wholly owned subsidiary, Alliance Pharmaceuticals, has acquired Opus Group Holdings for £8.0m plus the net asset value of Opus at completion (estimated at £1.5m). The Opus group sells products for stoma care, including skin creams and cleansers, in the UK and Ireland. In the year ended March 31st Opus delivered turnover of £3.8m and pre-tax profit of £2.1m. The consideration is being funded from existing cash and bank facilities.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Alexandr Wang: the AI wunderkind who takes his seat at MetaAlexandr Wang became the world’s youngest self-made billionaire by exploiting a niche in the AI market. Now Mark Zuckerberg has poached him for a record sum
-
Top global stocks offering rising income and lasting long-term growthOpinion Samantha Fitzpatrick, co-manager of the Murray International Trust, selects three global stocks where she’d put her money
